CKCarrie L. Kitko

Carrie L. Kitko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Carrie L. Kitko has a total of 369 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Acalabrutinib for Treatment of Steroid-Refractory Chronic Graft Versus Host Disease

    by Joseph Pidala, Hannah Choe, Amin Alousi, Carrie L. Kitko, Lynn Onstad, Rohtesh Mehta, Gabriela Desatnik, Qian V. Wu, Stephanie J. Lee

  • Open Access

    Clinical Predictors of Response in Chronic Graft‐Versus‐Host Disease: Results From the “Predicting the Quality of Response to Specific Treatments ( PQRST )” Trial

    by Betty K. Hamilton, Lynn Onstad, Paul A. Carpenter, Joseph Pidala, George Chen, Corey Cutler, Najla El Jurdi, Nosha Farhadfar, Mark Juckett, Carrie L. Kitko, et al.

    Despite significant progress in chronic GVHD therapies, challenges remain in understanding pleomorphic phenotypes and varying responses to treatment. The aim of this study was to identify predictors of treatment response. We conducted a prospective, observational cohort study of patients beginning first‐, second‐, or third‐line systemic therapy for chronic GVHD with defined agents. We describe best and 6‐month response rates, failure‐free survival (FFS), and clinical predictors of response. Best response rates were 60%–70% to index therapies, which subsequently declined to 40% at 6 months. Similarly, failure‐free survival at 6 months was 66%, but dropped to 41% at 18 months and did not vary based on agent or line of therapy. No clear clinical predictors of FFS or survival were identified. Patient‐reported fatigue was associated with NIH response, but we did not find any other clinical predictors of response. Six‐month responders were associated with higher FFS at 1 year. When patients were responding to therapy, more than one organ improved. Conversely, one organ usually accounted for patients progressing. In the contemporary era, we demonstrate high but not durable responses across all agents and the first three lines of therapy. There remain large variations in practice, and no specific patterns of agents used, organ responsiveness, or overall responsiveness were identified. Additional study is needed to identify clinical and biologic phenotypes and define predictors of treatment response. Trial Registration: clinicaltrials.gov identifier: NCT04431479.

  • Open Access

    Cognitive Functioning in Vorinostat‐Treated Pediatric and Young Adult Patients Over the First 180 Days After Hematopoietic Stem Cell Transplant

    by Kristen L. Votruba, Michelle Rozwadowski, Thomas Braun, April Rahrig, Edward Peres, Kirsten M. Williams, Vanessa Fabrizio, Julie‐An Talano, Carrie L. Kitko, Nicolas Parnell, et al.

    Purpose: Cognitive and psychological difficulties could negatively interfere with treatment adherence and quality of life before and after hematopoietic stem cell transplant (HSCT). Methods to mitigate these changes may have positive effects on treatment success. Prior work has shown that histone deacetylases (HDAC) inhibitors such as vorinostat show promise in reducing the incidence of graft‐versus‐host disease (GVHD) in allogenic transplant recipients and may mitigate some of the cognitive changes seen following transplant in adults. The current work presents a planned secondary analysis of a phase I/II trial of vorinostat for GVHD prophylaxis (NCT03842696) to establish a cognitive and psychological safety profile for use of this emerging therapeutic in a sample of children, adolescents, and young adults. Methods: Thirty‐two allogeneic transplant recipients (median age = 19) were evaluated with cognitive and health‐related quality‐of‐life (HRQL) measures prior to transplant and at 100 days and 180 days after transplant ( N = 25 (cognitive) and 25 (HRQL) at final endpoint). Kolmogorov–Smirnov tests and linear mixed effects modeling were used to compare cognitive performances and HRQL to normative levels and to examine changes over time. Results: Notable cognitive impairments prior to transplant remained relatively stable throughout the first 180 days post‐transplant, with no new neurocognitive safety signal over 180 days. Anxiety was apparent at baseline, but behavioral symptoms remained relatively well managed. Conclusion: Results highlight cognitive impairments present prior to transplant and support prior findings in an adult population, suggesting that vorinostat does not result in additional cognitive or psychological deficits following transplant.

  • Open Access

    Longitudinal Study of Late Acute and Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation: A Long-Term Follow-up Study from the Chronic Graft-Versus-Host Disease Consortium

    by Joseph Pidala, Lynn Onstad, Paul Carpenter, Betty K. Hamilton, Carrie L. Kitko, Mark Juckett, Corey Cutler, Stephanie J. Lee


  • Open Access

    Identification of Distinct Subtypes in Immune Tolerance after Hematopoietic Cell Transplantation Using the Prospective ABLE1.0 Pediatric Study Cohort

    by Bernard Ng, Andrew C. Harris, Sayeh Abdossamadi, Madeline P. Lauener, Geraldine Aubert, Rajinder Bajwa, Monica Bhatia, Henrique Bittencourt, Nataliya P. Buxbaum, Emi H. Caywood, et al.


  • Obesity Associations with Chronic Graft-Versus-Host Disease

    by Valentina Ardila, Lynn Onstad, Paul Carpenter, Joseph Pidala, Carrie Kitko, Najla El Jurdi, Stephanie J. Lee, Betty K. Hamilton


  • Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703

    by Shernan G. Holtan, Javier Bolaños-Meade, Monzr M. Al Malki, Juan Wu, Carrie L. Kitko, Ran Reshef, Andrew R. Rezvani, Brian C. Shaffer, Melhem M. Solh, Janny M. Yao, et al.

    The BMT CTN 1703 phase III trial confirmed that graft-versus-host disease (GVHD) prophylaxis with post-transplantation cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF) results in superior GVHD-free, relapse-free survival (GRFS) compared with Tac/methotrexate (MTX) prophylaxis. This companion study assesses the effect of these regimens on patient-reported outcomes (PROs). Using the Lee Chronic GVHD Symptom Score and PROMIS subscales (physical function, GI symptoms, social role satisfaction) as primary end points and hemorrhagic cystitis symptoms and Lee subscales as secondary end points, responses from English and Spanish speakers were analyzed at baseline and days 100, 180, and 365 after transplant. PRO scores were compared between the arms using inverse probability weighted-independent estimating equation models. The PTCy arm had significantly lower scores on the Lee Chronic GVHD Symptom Scale ( P = .01), indicating lower GVHD symptom burden. Lee Scale nutrition and mouth subscores were also better in the PTCy arm compared with the Tac/MTX arm ( P < .01 for both). Older participants (age >65 years) reported better Lee Scale psychological subscores than younger participants ( P = .003). No significant differences were identified in hemorrhagic cystitis or in the PROMIS subscales between treatment arms. The updated clinical end points at 2 years for the parent trial confirmed that PTCy/Tac/MMF maintained a significant advantage over Tac/MTX in GRFS (42.4% v 28.8%, P = .001). In addition to improved GRFS, patients randomly assigned to the PTCy arm reported lower symptom burden during the first year after transplant.


  • Open Access

    Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group

    by Nikolaos Katsivelos, Nikolaos Spyrou, Daniela Weber, Ingrid Vasova, Francis Ayuk, Hannah Choe, William Hogan, Zachariah DeFilipp, Muna Qayed, Aaron M Etra, et al.


  • Open Access

    Impact of the COVID‐19 Pandemic Onset on the Early Careers of Pediatric Oncology Health Professionals and Researchers: A Report From the Children's Oncology Group Young Investigators Committee, Young SIOP Network, and Young SIOPE

    by Gemma Bryan, Louise Guolla, Gabriela Inés Villanueva, Sarah Cohen‐Gogo, Alejandra Casanovas, Rina Medina, Gabriel Revon‐Riviere, Hallie Coltin, Lisa S. Kahalley, Janice S. Withycombe, et al.

    Introduction: The COVID‐19 pandemic onset had a global debilitating impact on individuals and on burgeoning careers. In 2021, the Children's Oncology Group Young Investigators Committee, Young SIOP (International Society of Paediatric Oncology) Network, and Young SIOPE (European Society for Paediatric Oncology) co‐sponsored a survey to explore the impacts of the first year of the pandemic on early‐career pediatric oncology professionals with respect to working practices, productivity, professional and career development, personal wellbeing, and changing childcare needs.Methods: The survey comprised demographic, multiple‐choice, and free‐text questions, and was distributed via email and social media with English, French, and Spanish versions available. Descriptive statistics and chi‐square tests were used to compare quantitative data by self‐designated gender and country of origin. Qualitative data were described using content analysis.Results: Professionals (N = 499, 26.3% male, 77.2% MDs) in 48 countries (77.6% high income) responded in English (79.4%), Spanish (12.4%), and French (8.2%). Respondents had difficulty obtaining and keeping jobs (26.9%), worsened overall academic productivity (50.7%, with higher rates among bench scientists, p < 0.01), and decreased career opportunities (40.9%). Childcare challenges impacted 56.7% of respondents and was felt more negatively among women (p = 0.008) and in high‐income settings (p < 0.0001). Qualitative data (n = 300) highlighted these differences were often attributable to diminished professional/personal boundaries and impacted their personal wellbeing.Conclusion: The COVID‐19 pandemic significantly impacted early‐career academic and clinical professionals working in pediatric oncology, with unique challenges noted among those with childcare responsibilities. Career disruptions that resulted from the pandemic should be considered and mitigated by governing bodies and hiring institutions.

  • A comprehensive assessment of the prolonged febrile neutropenia evaluation in pediatric oncology patients

    by Daniel A. Whitehurst, Debra L. Friedman, Zhiguo Zhao, Asha Sarma, Elizabeth Snyder, Daniel E. Dulek, Ritu Banerjee, Carrie L. Kitko, Adam J. Esbenshade

    Background: Pediatric oncology patients with prolonged (≥96 hours) febrile neutropenia (absolute neutrophil count < 500/μL) often undergo an evaluation for invasive fungal disease (IFD) and other infections. Current literature suggests that beta‐D‐glucan (BDG), galactomannan, bronchoalveolar lavage (BAL), and computed tomography (CT) scans (sinus, chest, and abdomen/pelvis) may help determine a diagnosis in this population.Methods: In a retrospective cohort study of all cancer/stem cell transplant patients (diagnosed 2005‐2019) from one pediatric hospital, all episodes with prolonged febrile neutropenia or IFD evaluations (defined as sending a fungal biomarker or performing a CT scan to assess for infection) were identified.Results: In total, 503 episodes met inclusion criteria and 64% underwent IFD evaluations. In total, 36.4% of episodes documented an infection after initiation of prolonged febrile evaluation, most commonly Clostridioides difficile colitis (6.4%) followed by a true bacterial bloodstream infection (BSI) (5.2%), proven/probable IFD (4.8%), and positive respiratory pathogen panel (3.6%). There was no difference in sinus CTs showing sinusitis (74% vs 63%, p = 0.46), whereas 32% of abdomen/pelvis CTs led to a non‐IFD diagnosis, and 25% of chest CTs showed possible pneumonia. On chest CT, the positive predictive value (PPV) for IFD was 19% for nodules and 14% for tree and bud lesions. BDG had a PPV of 25% for IFD and GM 50%. BAL diagnosed IFD once and pneumocystis jirovecii pneumonia twice.Conclusions: Chest CTs and abdomen/pelvis CTs provide clinically relevant information during the prolonged febrile neutropenia evaluation, whereas BDG, galactomannan, BAL, and sinus CTs have less certain utility.